[ARGS] Argos Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.6 Change: 0.2 (4.55%)
Ext. hours: Change: 0 (0%)

chart ARGS

Refresh chart

Strongest Trends Summary For ARGS

ARGS is in the long-term down -100% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its products include AGS-003, which is under Phase III clinical trials and intended for the treatment of metastatic renal cell carcinoma (clear cell); and AGS-004, which is under Phase IIb clinical trials and is intended for the treatment of Human Immunodeficiency Virus. The company also develops AGS-003 for metastatic renal cell carcinoma (non-clear cell), early stage RCC, and other solid tumors. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.

Fundamental Ratios
Shares Outstanding EPS-1.1 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -62.16% Sales Growth - Q/Q-40.92% P/E-0.35
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-114.18% ROE-408.31% ROI
Current Ratio7.22 Quick Ratio Long Term Debt/Equity0.74 Debt Ratio0.38
Gross Margin Operating Margin-4392.69% Net Profit Margin-4494.17% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities180 K Cash From Investing Activities6.21 M Cash From Operating Activities-14.57 M Gross Profit
Net Profit-17.55 M Operating Profit-16.96 M Total Assets53.29 M Total Current Assets40.39 M
Total Current Liabilities5.6 M Total Debt29.75 M Total Liabilities38.39 M Total Revenue180 K
Technical Data
High 52 week3.46 Low 52 week0.02 Last close0.06 Last change-14.29%
RSI71.58 Average true range0.02 Beta0.93 Volume148.63 K
Simple moving average 20 days23.52% Simple moving average 50 days-29.43% Simple moving average 200 days-67.27%
Performance Data
Performance Week-14.29% Performance Month-3.23% Performance Quart-70.73% Performance Half-61.32%
Performance Year-97.86% Performance Year-to-date100% Volatility daily27.39% Volatility weekly61.24%
Volatility monthly125.5% Volatility yearly434.75% Relative Volume414.79% Average Volume55.82 K
New High New Low

News

2018-08-31 08:25:00 | New Research Coverage Highlights Argos Therapeutics, Triumph Group, Rigel Pharmaceuticals, Egalet, Hertz Global, and ACADIA Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-05-16 07:05:00 | Free Stock Performance Review on Array BioPharma and Three More Biotech Industry

2018-04-27 08:30:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Bottomline Technologies, SkyWest, Pacific Biosciences of California, Argos Therapeutics, Luminex, and Fiserv — New Research Emphasizes Economic Growth

2018-04-19 12:43:15 | Argos discontinues troubled trial, delists from Nasdaq

2018-04-19 12:31:15 | Here’s What’s Dragging Argos Therapeutics ARGS Stock Down Today

2018-04-19 08:00:00 | Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives

2018-04-13 07:20:00 | Blog Exposure - Alexion Pharma to Acquire Swedish Biotech Wilson Therapeutics

2018-04-12 08:30:00 | Today’s Research Reports on Trending Tickers: Argos Therapeutics and Bellicum Pharmaceuticals

2018-04-02 08:50:37 | Argos Therapeutics reports 4Q loss

2018-04-02 08:30:00 | Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights

2018-03-28 17:00:00 | Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018

2018-03-01 08:15:00 | Detailed Research: Economic Perspectives on Navigant Consulting, CalAmp, Sonoco Products, Argos Therapeutics, K2M Group, and Altra Industrial Motion — What Drives Growth in Today's Competitive Landscape

2018-02-15 08:30:00 | Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy

2018-02-12 17:09:37 | A Daytrader's Guide To Fear

2018-02-07 08:30:00 | Today’s Research Reports on Trending Tickers: Argos Therapeutics and Sorrento Therapeutics

2018-02-05 16:47:16 | Argos Obtains Option to License PD1 Checkpoint Inhibitors

2018-01-30 19:51:15 | Where Argos Therapeutics Inc NASDAQ:ARGS Stands In Terms Of Earnings Growth Against Its Industry

2018-01-22 17:55:11 | Heat latest Triangle biopharma to execute reverse stock split

2018-01-19 14:15:08 | Argos executes reverse stock split

2018-01-18 08:00:00 | Argos Announces One-for-Twenty Reverse Stock Split

2018-01-08 08:30:00 | Argos Announces $1.5 Million Equity Investment by Lummy Hong Kong, Ltd.

2018-01-04 08:10:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Sonoco Products, Argos Therapeutics, CDW, Cenveo, CoBiz Financial, and Oppenheimer — New Research Emphasizes Economic Growth

2017-12-29 12:25:09 | Should You Worry About Argos Therapeutics Inc’s NASDAQ:ARGS CEO Pay?

2017-12-22 11:32:10 | ETFs with exposure to Argos Therapeutics, Inc. : December 22, 2017

2017-12-14 11:15:10 | One Thing To Consider Before Buying Argos Therapeutics Inc NASDAQ:ARGS

2017-12-11 13:29:57 | ETFs with exposure to Argos Therapeutics, Inc. : December 11, 2017

2017-12-05 10:55:08 | With 42.3% Earnings Growth Lately, Did Argos Therapeutics Inc ARGS Outperform The Industry?

2017-11-30 13:23:50 | ETFs with exposure to Argos Therapeutics, Inc. : November 30, 2017

2017-11-29 07:48:03 | Argos Therapeutics, Inc. :ARGS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

2017-11-28 08:00:00 | Argos Provides Financial Update

2017-11-13 10:19:42 | Edited Transcript of ARGS earnings conference call or presentation 13-Nov-17 1:30pm GMT

2017-11-13 06:15:00 | Argos Therapeutics, Inc. to Host Earnings Call

2017-11-11 08:30:00 | Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting

2017-11-10 05:01:40 | Argos Therapeutics reports 3Q loss

2017-11-09 16:46:32 | Argos Reports Third Quarter 2017 Financial Results and Operational Highlights

2017-11-09 12:05:00 | Argos Therapeutics, Inc. to Host Earnings Call

2017-11-06 16:30:00 | Argos Announces Receipt of Milestone Payment from Lummy Hong Kong Co. Ltd.

2017-11-06 11:05:51 | ETFs with exposure to Argos Therapeutics, Inc. : November 6, 2017

2017-11-06 10:04:24 | Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017

2017-11-01 21:01:30 | Who Are The Major Shareholders Of Argos Therapeutics Inc ARGS?

2017-10-25 09:49:52 | ETFs with exposure to Argos Therapeutics, Inc. : October 25, 2017

2017-10-18 20:11:31 | NasdaqGM Healthcare Industry: A Deep Dive Into Argos Therapeutics Inc ARGS

2017-10-11 11:11:18 | ETFs with exposure to Argos Therapeutics, Inc. : October 11, 2017

2017-09-26 16:30:00 | Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors

2017-09-26 10:41:07 | ETFs with exposure to Argos Therapeutics, Inc. : September 26, 2017

2017-09-19 08:30:00 | Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress

2017-09-18 10:49:10 | Argos Therapeutics Inc ARGS: What Does It Mean For Your Portfolio?

2017-09-12 08:00:00 | Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress

2017-09-11 20:50:25 | ETFs with exposure to Argos Therapeutics, Inc. : September 12, 2017

2017-09-06 08:00:00 | Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir